Added to YB: 2025-10-30
Pitch date: 2025-10-28
NOVN.SW [neutral]
Novartis AG
+7.87%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Market Cap
CHF 243.9B
Pitch Price
CHF 97.80
Price Target
N/A
Dividend
3.40%
EV/EBITDA
10.59
P/E
17.42
EV/Sales
4.73
Sector
Pharmaceuticals
Category
N/A
Novartis (NOVN Switzerland): Resilience in revenue, but margins feel the weight of reinvestment
NOVN.SW (quick overview): Q3 showed mid-single digit revenue growth led by Kisqali (oncology) & Kesimpta (neurology), but core operating margins compressed from stepped-up R&D spending on late-stage pipeline programs. Entresto facing US generic pressure offset by international demand. Trades inline with pharma peers, needs pipeline evidence to offset patent erosion for re-rating catalyst.
Read full article (2 min)